• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    EDAP TMS S.A. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/26/26 4:05:17 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $EDAP alert in real time by email
    false --12-31 0001041934 0001041934 2026-06-26 2026-06-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 26, 2026

     

    EDAP TMS SA

    (Exact name of Registrant as specified in its charter)

     

    France 000-29374 98-1644844

    (State or other jurisdiction of incorporation)

    (Commission File No.)

    (I.R.S. Employer Identification No.)

     

    Parc d’Activites la Poudrette-Lamartine

    4/6, rue du Dauphiné

    Vaulx-en-Velin, France 69120

    (Address of Principal Executive Offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (+33) 47-215-3150

     

    Not Applicable

    (Former name or former address if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    _______________________________

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered
    American Depositary Shares, each representing one Ordinary Share (Ordinary Shares, nominal value €0.13 per share) FOCL NASDAQ Global Market

     

    Indicated by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐ 

     

     

     

     

    Item 5.03Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    At the 2026 Annual General Meeting of Shareholders (the “2026 Annual General Meeting”) of EDAP TMS S.A. (the “Company”) held on June 26, 2026, the Company’s shareholders approved amendments to the bylaws (statuts) of the Company, effective June 26, 2026. The amendments (i) amend Articles 7 and 8 of the bylaws (relating to the share capital), (ii) amend Article 14 of the bylaws (relating to the Board of Directors), (iii) amend Article 22 of the bylaws (relating to the Shareholders’ Meeting), and (iv) effect certain nonmaterial amendments to Articles 9, 20, 21, 26, 30 and 31 of the bylaws, in each case as approved under Resolutions 29 through 32 described in Item 5.07 below.

     

    The foregoing description of the amendments to the bylaws is qualified in its entirety by reference to the full text of the amended bylaws, the English translation of which is attached hereto as Exhibit 3.1 and incorporated herein by reference.

     

    Item 5.07Submission of Matters to a Vote of Security Holders.

     

    On June 26, 2026, the Company held the 2026 Annual General Meeting at its registered office located at Parc d’Activites la Poudrette-Lamartine, 4/6, rue de Dauphiné, 69120 Vaulx-en-Velin, France. A total of 37,484,065 Ordinary Shares (including Ordinary Shares represented by American Depositary Shares) were represented and voted at the 2026 Annual General Meeting. The number of votes cast for and against, and the number of abstentions, with respect to each matter voted upon at the 2026 Annual General Meeting are set forth below.

     

    Ordinary Shares underlying American Depositary Shares for which the depositary (the “Depositary”) did not receive timely voting instructions were voted by the Depositary, or by the Depositary’s discretionary proxy, in accordance with the recommendations of the Board of Directors, as described in the proxy statement for the 2026 Annual General Meeting; accordingly, there were no broker non-votes with respect to any matter.

     

    1. The resolution renewing the term of office of Ryan Rhodes as director was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    36,821,142 476,781 186,142

     

    2. The resolution renewing the term of office of Dr. Lance Willsey as director was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    36,680,178 617,745 186,142

     

    3. The resolution renewing the term of office of Fran Schulz as director was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    36,835,613 467,444 181,008

     

    4. The resolution renewing the term of office of Josh Levine as director was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    37,168,687 134,581 180,797

     

     

     

     

    5. The resolution ratifying the temporary appointment of David Horn as director decided by the Board of Directors on February 11, 2026 was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    37,179,197 109,071 195,797

     

    6. The resolution renewing the term of office of David Horn as firector was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    37,170,082 109,116 204,867

     

    7. The resolution approving the related-person agreements referred to in Article L. 225-38 of the French Commercial Code was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    36,366,419 803,798 313,848

     

    8. The resolution approving the statutory financial statements for the fiscal year ended December 31, 2025 was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    37,057,443 375,170 51,452

     

    9. The resolution approving the consolidated financial statements (US GAAP and IFRS) for the fiscal year ended December 31, 2025 was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    37,063,766 385,370 34,929

     

    10. The resolution approving the allocation of the results for the fiscal year ended December 31, 2025 was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    37,033,713 375,193 75,159

     

    11. The resolution renewing the term of office of AGILI3F as statutory auditor was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    36,892,459 392,508 199,098

     

     

     

     

    12. The resolution approving, on a non-binding advisory basis, the compensation of the named executive officers of the Company was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    36,248,209 1,070,150 165,706

     

    13. The resolution recommending, on a non-binding advisory basis, that future non-binding advisory votes on the compensation of the named executive officers of the Company be held every year was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    36,249,837 1,071,631 162,597

     

    14. The resolution recommending, on a non-binding advisory basis, that future non-binding advisory votes on the compensation of the named executive officers of the Company be held every two years was not approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    8,200,822 29,093,425 189,818

     

    15. The resolution recommending, on a non-binding advisory basis, that future non-binding advisory votes on the compensation of the named executive officers of the Company be held every three years was not approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    8,323,552 28,970,695 189,818

     

    16. The resolution delegating authority to the Board of Directors to increase the share capital, by issuance of shares or other securities giving access to the Company’s share capital, with preferential subscription rights for shareholders was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    35,652,807 1,795,765 35,493

     

    17. The resolution delegating authority to the Board of Directors to increase the share capital, by issuance of shares or other securities giving access to the Company’s share capital, with cancellation of shareholders’ preferential subscription rights, by means of a public offering (excluding offerings referred to in paragraph 1 of Article L. 411-2 of the French Monetary and Financial Code) was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    35,109,152 2,328,650 46,263

     

     

     

     

    18. The resolution delegating authority to the Board of Directors to increase the share capital, by issuance of shares or other securities giving access to the Company’s share capital, with cancellation of shareholders’ preferential subscription rights, through an offer referred to in paragraph 1 of Article L. 411-2 of the French Monetary and Financial Code was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    35,106,547 2,326,511 51,007

     

    19. The resolution delegating authority to the Board of Directors to increase the share capital, by issuance of shares or other securities giving access to the Company’s share capital, with cancellation of shareholders’ preferential subscription rights, in favor of a first category of persons who meet certain specified characteristics was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    35,091,840 2,345,437 46,788

     

    20. The resolution delegating authority to the Board of Directors to increase the share capital, by issuance of shares or other securities giving access to the Company’s share capital, with cancellation of shareholders’ preferential subscription rights, in favor of a second category of persons who meet certain specified characteristics was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    35,302,845 2,076,762 104,458

     

    21. The resolution delegating authority to the Board of Directors to increase the share capital, by issuance of shares or other securities giving access to the Company’s share capital, with cancellation of shareholders’ preferential subscription rights, in favor of a third category of persons who meet certain specified characteristics was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    35,233,170 2,146,437 104,458

     

    22. The resolution delegating authority to the Board of Directors to increase the number of securities to be issued in the event of a capital increase, with or without preferential subscription rights, decided pursuant to the foregoing delegations was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    35,386,773 1,995,094 102,198

     

    23. The resolution delegating authority to the Board of Directors to decide on any merger-absorption, spin-off or partial contribution of assets was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    36,397,257 986,288 100,520

     

    24. The resolution delegating authority to the Board of Directors to issue ordinary shares giving, as the case may be, access to ordinary shares or to the allocation of debt securities (of the Company or of a group company), and/or securities giving access to ordinary shares (of the Company or of a group company), in the context of a merger, spin-off or partial contribution of assets decided by the Board of Directors pursuant to Resolution 23 was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    35,751,819 1,652,962 79,284

     

     

     

     

    25. The resolution determining the overall maximum amount applicable to the financial delegations granted to the Board of Directors to increase the share capital pursuant to Resolution 16 through Resolution 24 was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    35,501,019 1,902,622 80,424

     

    26. The resolution delegating authority to the Board of Directors to increase the share capital, by issuance of shares or other securities giving access to the Company’s share capital, with cancellation of shareholders’ preferential subscription rights, in favor of the European Investment Bank (the “EIB”) or any entity succeeding the EIB in connection with any financing contract was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    35,690,312 1,721,195 72,558

     

    27. The resolution authorizing the Board of Directors to grant existing and/or newly issued free shares of the Company to all or certain employees and/or all or certain corporate officers of the Company or companies in the group, in accordance with the provisions of Articles L. 225-197-1 et seq. of the French Commercial Code, with automatic waiver of the shareholders’ preferential subscription rights for the new shares that may be issued was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    35,699,794 1,653,657 130,614

     

    28. The resolution delegating authority to the Board of Directors to increase the Company’s share capital for the benefit of employees who are members of a company savings plan(s) (plan(s) d’épargne d’entreprise) implemented pursuant to Articles L. 3332-1 et seq. of the French Labor Code was not approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    8,440,182 28,912,550 131,333

     

    29. The resolution approving amendments to Articles 7 and 8 of the bylaws of the Company (articles related to share capital) was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    36,457,465 828,770 197,830

     

    30. The resolution approving amendments to Article 14 of the bylaws of the Company (article related to the Board of Directors) was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    36,487,556 799,770 196,739

     

     

     

     

    31. The resolution approving amendments to Article 22 of the bylaws of the Company (article related to the Shareholders’ Meeting) was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    36,522,806 740,484 220,775

     

    32. The resolution approving nonmaterial amendments to the bylaws of the Company was approved, based upon the following votes:

     

    Voted For Voted Against Abstained
    36,810,767 552,014 121,284

     

    Item 9.01Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
       
    3.1   Update to the bylaws (statuts) of EDAP TMS S.A. (English translation)
    104   Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      EDAP TMS S.A.
         
    Date: June 26, 2026 By: /s/ Sanket Shah
        Sanket Shah
       

    General Counsel and Corporate Secretary

     

     

     

     

     

     

     

     

     

     

    Get the next $EDAP alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EDAP

    DatePrice TargetRatingAnalyst
    5/15/2025Overweight → Neutral
    Piper Sandler
    4/4/2025$2.00Buy → Hold
    Jefferies
    11/1/2022$11.00Buy
    Jefferies
    11/19/2021$12.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $EDAP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Marketing & Product Mgmt. Annen Steven was granted 90,000 shares, increasing direct ownership by 217% to 131,490 units (SEC Form 4)

    4 - EDAP TMS SA (0001041934) (Issuer)

    5/13/26 6:05:24 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Levine Joshua bought $42,200 worth of shares (10,000 units at $4.22), increasing direct ownership by 40% to 35,000 units (SEC Form 4)

    4 - EDAP TMS SA (0001041934) (Issuer)

    5/13/26 6:03:23 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Gen Counsel & Corp Secretary Shah Sanket was granted 67,500 shares (SEC Form 4)

    4 - EDAP TMS SA (0001041934) (Issuer)

    5/13/26 6:05:04 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    EDAP TMS SA downgraded by Piper Sandler

    Piper Sandler downgraded EDAP TMS SA from Overweight to Neutral

    5/15/25 1:10:07 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP TMS SA downgraded by Jefferies with a new price target

    Jefferies downgraded EDAP TMS SA from Buy to Hold and set a new price target of $2.00

    4/4/25 8:36:35 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Jefferies initiated coverage on EDAP TMS SA with a new price target

    Jefferies initiated coverage of EDAP TMS SA with a rating of Buy and set a new price target of $11.00

    11/1/22 6:28:24 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Levine Joshua bought $42,200 worth of shares (10,000 units at $4.22), increasing direct ownership by 40% to 35,000 units (SEC Form 4)

    4 - EDAP TMS SA (0001041934) (Issuer)

    5/13/26 6:03:23 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    SEC Filings

    View All

    EDAP TMS S.A. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - EDAP TMS SA (0001041934) (Filer)

    6/26/26 4:05:17 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP TMS S.A. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - EDAP TMS SA (0001041934) (Filer)

    6/1/26 4:05:28 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP TMS S.A. filed SEC Form 8-K: Other Events

    8-K - EDAP TMS SA (0001041934) (Filer)

    5/29/26 7:30:18 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy

    , May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol "FOCL" at Market Open on June 1, 2026Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments as Discontinued Operations Beginning with Second Quarter 2026 Financial ResultsInvestor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity AUSTIN, Texas, May 29, 2026 - EDAP TMS S.A. (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, today announce

    5/29/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference

    , May 21, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Present at Jefferies 2026 Global Healthcare Conference Company to Present and Host 1x1 Investor Meetings on Thursday, June 4th, 2026 AUSTIN, Texas, May 21th, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to present and, together with Ken Mobeck, Chief Financial Officer, will host 1x1 investor meetings at the upcoming Jefferies 2026 Global Healthcare Conference in New York. Date: Thursday, June 4th Time: 2:00-2:30 PM ET Format: Presentation and 1x1 investor meetings Webcast: https://event.summitcast.com

    5/21/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches

    Telix to partner with companies developing advanced minimally invasive and image-guided ablative technologies for prostate cancer.Initial focus on patient selection, treatment planning and post-treatment monitoring; evidence generation to inform best practice.Aim to accelerate adoption of novel therapeutic workflows to enhance clinical decision making and patient outcomes. MELBOURNE, Australia and INDIANAPOLIS, May 15, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, "Telix") today announces that it has entered into letters of intent to pursue collaborations with EDAP TMS S.A. (NASDAQ:EDAP, "EDAP")) and Profound Medical Corp. (NASDAQ:PROF, TSX:PRN, "Profound")

    5/15/26 6:30:00 AM ET
    $EDAP
    $PROF
    $TLX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Medical/Dental Instruments
    Biotechnology: Pharmaceutical Preparations

    $EDAP
    Financials

    Live finance-specific insights

    View All

    EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue

    , May 07, 2026 (GLOBE NEWSWIRE) -- EDAP Reports Strong Financial Results with Record First Quarter HIFU Revenue Seventh Consecutive Quarter of Year-Over-Year HIFU Revenue Growth 78% Growth in First Quarter HIFU Revenue Year-Over-Year53% Growth in First Quarter U.S. HIFU Procedures Year-Over-Year83% Growth in First Quarter Focal One Shipments Year-Over-Year Demonstrating Strong MomentumLandmark HIFI-2 Study Results Further Strengthen Focal One Robotic HIFU Market Position AUSTIN, Texas, May 7, 2026 - EDAP TMS SA (NASDAQ:EDAP), the global leader in robotic energy-based therapies, today reported financial results for the first quarter of 2026. "We delivered our strongest HIFU quarter t

    5/7/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026

    , April 16, 2026 (GLOBE NEWSWIRE) -- EDAP to Announce First Quarter 2026 Financial Results on May 7, 2026 Company to host conference call and webcast on Thursday, May 7 at 8:30 a.m. EDT AUSTIN, Texas, April 16, 2026 -- EDAP TMS SA (NASDAQ:EDAP) ("the Company"), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the first quarter ended March 31, 2026, before market open on Thursday, May 7, 2026. An accompanying conference call and webcast will be conducted by Ryan Rhodes, Chief Executive Officer, Ken Mobeck, Chief Financial Officer, and François Dietsch, Chief Accounting Officer. Please refer to the information below for c

    4/16/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue

    EDAP Reports Record Fourth Quarter and Full-Year 2025 HIFU Revenue 39% Full-Year YoY HIFU Revenue Growth, Record Performance Driven by Increased Focal One® System Sales and Growth in the Number of U.S. Focal One Procedures69% Full-Year YoY Growth in Focal One System Placements28% Q4 YoY Growth in U.S. Procedures, Marking the Second Consecutive Quarter of Double-Digit Procedure GrowthDemand for Focal One Systems Remains Strong with System Placements in Academic Cancer Centers, Community Hospitals, and Large Integrated Healthcare Networks Company Reiterates its Previously Issued 2026 Revenue Guidance; HIFU Revenue Expected to Grow Between 34% and 45% YoY AUSTIN, Texas, March 25, 2026 - E

    3/25/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Leadership Updates

    Live Leadership Updates

    View All

    EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy

    , May 29, 2026 (GLOBE NEWSWIRE) -- EDAP Announces Corporate Name Change to FocalTherics™ to Reflect Exclusive Focus on High-Growth Robotic Focal Therapy Company will Begin Trading Under New Ticker Symbol "FOCL" at Market Open on June 1, 2026Company Intends to Report and Classify its Legacy Non-Core ESWL and Distribution Operating Segments as Discontinued Operations Beginning with Second Quarter 2026 Financial ResultsInvestor Day to be Held on June 1, 2026 to Highlight Company Vision and Long-Term Strategy under New FocalTherics Corporate Identity AUSTIN, Texas, May 29, 2026 - EDAP TMS S.A. (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, today announce

    5/29/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP | Focal One to Host Investor Day on June 1, 2026

    , May 13, 2026 (GLOBE NEWSWIRE) -- EDAP | Focal One to Host Investor Day on June 1, 2026 AUSTIN, Texas, May 13, 2026 -- EDAP TMS SA (NASDAQ:EDAP) (the "Company"), the global leader in robotic energy-based therapies, today announced that it will host an Investor Day for analysts and investors at 8:00 am ET on Monday, June 1, 2026. The presentation will be led by members of the Company's Executive Leadership Team and will include remarks from a prominent urologic surgeon and expert in focal therapy and Focal One HIFU. The event will also cover an overview of the Company's business plans and strategic path forward, including our: Growth Strategy and Long-Term Financial TargetsExpanding Th

    5/13/26 4:30:00 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    EDAP Announces Appointment of David Horn to Board of Directors

             EDAP Announces Appointment of David Horn to Board of Directors AUSTIN, Texas, February 12, 2026 – EDAP TMS S.A. (NASDAQ:EDAP) ("the Company" or "EDAP"), a global leader in therapeutic ultrasound technology, today announced the appointment of David Horn to its Board of Directors, effective February 11, 2026. The addition of Mr. Horn strengthens the Board with extensive experience both advising and leading companies through periods of strategic growth and transformation. Mr. Horn will serve as a member of the Company's Audit Committee and Nominations Committee. "We are pleased to welcome David to the EDAP Board," said Lance Willsey, Chairman of the Board of EDAP. "David brings dee

    2/12/26 7:30:00 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EDAP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by EDAP TMS S.A.

    SC 13G/A - EDAP TMS SA (0001041934) (Subject)

    11/14/24 3:36:33 PM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by EDAP TMS S.A. (Amendment)

    SC 13G/A - EDAP TMS SA (0001041934) (Subject)

    2/2/24 9:41:45 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G/A filed by EDAP TMS S.A. (Amendment)

    SC 13G/A - EDAP TMS SA (0001041934) (Subject)

    2/14/23 8:19:52 AM ET
    $EDAP
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care